Haleon Pakistan Limited (HALEON): Strategic Expansion to Improve Margins – By Sherman Research
Jan 3 2025
Sherman Securities
- Haleon Pakistan Limited is a consumer healthcare company with a diverse portfolio, featuring well-known brands such as Panadol, CaC1000, and Sensodyne.
- Investor optimism in the pharmaceutical sector is rising, fueled by a stable exchange rate and a decline in global raw material prices. Notably, over the past six months, the pharmaceutical sector has surged by 107% (adjusted for BFBIO), outperforming the KSE-100 index by 65%.
- Meanwhile, the government has increased local prices for essential drugs in line with inflation, while deregulating prices for non-essential drugs, which has led to improved margins. Haleon stands to benefit significantly from this shift, as over 53% of its revenue comes from non-essential products, positioning it as a major beneficiary of the new pricing dynamics.
Current:
Open:
Volume:
Change: ()
High:
Low:
52 Week High:
Vol Avg(12 m):
Free Float:
52 Week Low:
Market Cap:
Total Share:
Relative Strength Index (RSI)
RSI:
MACD Signals
MACD DAILY:
MACD WEEKLY:
Simple Moving Avg (SMA)
SMA(10):
SMA(30):
SMA(60):
SMA(200):
Performance
One Month:
Three Months:
Six Months:
Twelve Months:
Support & Resistance
Support 1:
Resistance 1:
Support 2:
Resistance 2:
High & Lows
Period
High
Low